Antibody Approach To CGRP Offers Safer Mode For Migraine Prevention, Labrys Says
This article was originally published in The Pink Sheet Daily
Labrys is ready to advance a monoclonal antibody to Phase II for prevention of chronic migraine, after releasing pooled safety from five Phase I trials conducted by Pfizer.
You may also be interested in...
venBio Rings In 2013 With Two Company Launches
New venture firm venBio, which closed its inaugural $200 million fund in 2010, has begun the new year by unveiling two start ups with very different business propositions.
Merck Gets A Headache: Unexpectedly Halts Development Of Migraine Drug
Meanwhile, the drug maker hopes to file a different drug, talcagepant, to treat acute migraines, but has yet to say when that will happen.
ImmunoGen’s Elahere Data In Avastin-Naïve Ovarian Cancer Prompt Discussion About Earlier Use
The presenter on the MIRASOL study called the data “practice changing,” while the discussant cited Sutro’s STRO-002 as a potential option for patients with low folate receptor alpha expression.